BridgeBio Pharma, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- BridgeBio Pharma, Inc. payments for repurchase of common stock for the quarter ending 2026-06-30 was $127.50M.
- BridgeBio Pharma, Inc. payments for repurchase of common stock for the quarter ending 2026-03-31 was $82.50M, a 70.89% increase year-over-year.
- BridgeBio Pharma, Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00.
- BridgeBio Pharma, Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00.
- BridgeBio Pharma, Inc. payments for repurchase of common stock for fiscal 2025 was $48.28M.
- BridgeBio Pharma, Inc. payments for repurchase of common stock for fiscal 2024 was $0.00.
- BridgeBio Pharma, Inc. payments for repurchase of common stock for fiscal 2023 was $0.00.
- BridgeBio Pharma, Inc. payments for repurchase of common stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $127.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $210.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $82.50M 10-Q · filed 2026-05-07 | $82.50M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $48.28M 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $48.28M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $48.28M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $48.28M 10-Q · filed 2026-05-07 | $48.28M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 | |
| 2023-12-31 | $0.00 10-K · filed 2026-02-24 | |
| 2022-12-31 | $0.00 10-K · filed 2024-02-22 | |
| 2021-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $200.00M 10-K · filed 2024-02-22 |
| 2021-09-30 | $143.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $198.46M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $5.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $55.31M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $50.00M 10-Q · filed 2022-05-05 | $50.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $75.00M 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | |
| 2020-03-31 | $75.00M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |